Shoulder Innovations 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 net revenue was $16.2 million, up 38% year over year from $11.8 million.
- Implant systems sold increased 34% year over year to 2,126 units, and gross margin was 78.5%, compared with 76.2% in the prior year.
- Selling, general, and administrative expenses were $17.1 million, compared with $15.1 million, while research and development expenses were $3.2 million, compared with $1.5 million.
- Net loss was $7.0 million, compared with $8.7 million, and adjusted EBITDA loss was $5.5 million, compared with $7.5 million.
- Cash, cash equivalents, and marketable securities were $92.3 million as of September 30th, 2026; cash burn improved in Q3 compared to Q2.
- The company launched InSet Go, received FDA clearance for and launched the N22 humeral head, and released a new version of ProVoyance.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome, ladies and gentlemen, to the third quarter 2026 earnings conference call for Shoulder Innovations. At this time, all participants have been placed in a listen-only mode. At the end of the company's prepared remarks, we will conduct a question-and-answer session. Please note that this conference is being recorded and will be available on the company's website for replay shortly. I will now turn the call over to Sam Bentzinger, Investor Relations at Gilmartin Group, for a few introductory comments.
Please go ahead. Good afternoon, and thank you for participating in today's call.
Joining me from Shoulder Innovations are Rob Ball, Chief Executive Officer, and Jeff Points, Chief Financial Officer. Earlier today, Shoulder Innovations issued a press release announcing financial results for the third quarter ended September 30, 2026. A copy of the press release is available on the Investor Relations section of the company's website. Before we begin, I would like to remind you that management will make remarks during this call that constitute forward-looking statements within the meaning of federal securities laws, and that these are being made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements.
These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. Additionally, during this conference call, the company will discuss certain financial measures that have not been prepared in accordance with GAAP. This non-GAAP information should not be considered in isolation or as a substitute for or superior to results prepared in accordance with GAAP. Please refer to the table in our earnings release for a reconciliation of these measures to the most directly comparable GAAP financial measure.
This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 5, 2026. Shoulder Innovations disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. With that, I will now turn the call over to Rob.
Thanks, Sam. Good afternoon, everyone, and welcome to our third quarter earnings call. Q3 marked another quarter of strong growth and execution for Shoulder Innovations, and I am looking forward to walking through both our commercial performance and several product and pipeline updates. Our third quarter results reflect the consistency of our commercial model, especially through what is typically the slowest stretch of the orthopedic calendar. We added new surgeons ahead of plan, grew volume within our existing customer base, and kept product roadmap moving, including launching the InSet Go, our next generation glenoid implant. Third quarter net revenue was $16.2 million, an increase of 38% year-over-year. Q3 gross margin was also strong at 78.5%, up year-over-year and sequentially.
Sustained pricing discipline and our cost-down programs continue to strengthen our margin profile, and Jeff will cover the additional cost initiatives that we expect to contribute beginning in 2027. We were also pleased to see the favorable CMS final rulings related to shoulder arthroplasty published yesterday evening. We are proud to have delivered these results through the normal summer seasonality as we saw across the orthopedic market, which we anticipated on our last call and incorporated into our guidance at that time. Notwithstanding, the impact of seasonality amongst our more tenured core surgeons was more pronounced this quarter as compared to the third quarter of 2025. However, as was the case in 2025, new customer additions in Q3 drove significantly above market growth despite these dynamics.
With three strong quarters behind us, we are again raising our full year 2026 net revenue guidance to the range of $68 million-$70 million, representing growth of 44%-48% over 2025. This compares to our prior range of $67 million-$69 million, or 42%-46% growth. As is typical, procedure volumes began to improve in September, and we have been encouraged by the start to the fourth quarter. The pace of new surgeon activity and the depth of our funnel underpin the confidence behind our updated outlook. Our progress this quarter maps directly to the three strategic priorities that guide how we invest our time and resources. These include driving adoption among new surgeons, increasing penetration in our existing surgeon customer base to increase procedural volume, and adding products to our portfolio to address the unmet needs of patients and surgeons.
Beginning with new surgeon adoption, we again added new customers into our core contender and prospect funnel at a pace ahead of our expectations in the third quarter, as we have done every quarter this year. Our W2 commercial organization remains focused on the roughly 1,800 high-volume shoulder specialists in the U.S., and that targeted approach continues to translate into steady growth in our customer base. We expect that momentum to be durable as we close out the year. To support this momentum, we have accelerated our hiring plans, again adding top talent to our commercial leadership team through the third quarter, and further additions continuing in the early weeks of Q4 as well.
The 2025 cohort of commercial leaders has been a meaningful contributor to our growth this year, and we expect this year's hires to follow a similar path as they ramp, with our business intelligence platform helping each of them prioritize the right surgeon targets from day one. Additionally, surgeon-to-surgeon education remains one of the most effective tools we have for converting new customers. Our CEME team has now carried out more than 150 surgeon engagement events so far this year. In August, we hosted our InSet Society meeting alongside our national sales meeting, which together drew approximately 250 attendees. The energy and optimism across both simultaneous events were outstanding, and the R&D initiatives we outlined on our last call were exceptionally well received by our surgeon partners. Even further, just after quarter end, we hosted our second national symposium of 2026.
After a record turnout at our spring symposium earlier in the year, this event drew even more healthcare providers, making it our largest and most successful symposium to date. The event generated numerous new surgeon conversions, and we believe these programs strengthen our brand and lay the foundation for future growth. Regarding our second priority, increasing utilization and procedural growth within our customer base, third quarter implant volume across our core contender and prospect customers grew approximately 34% year over year to 2,126 units. When we look at our customer base by annual cohort, we continue to see each group of surgeons grow its volume over time, with average volume per cohort increasing from 24 to 25, and again so far in 26. Within that, the majority of our implant volume growth this quarter was again derived from our core surgeon category.
We've seen marked increases in productivity among both the core and contender groups. Put simply, the prospect to contender to core progression we've described since our first earnings call continues to play out as designed, and with new surgeons entering the funnel at a steady pace, our base of future core surgeons keeps growing. We believe this predictability is one of the most important value drivers of our business. We also continue to expand our geographic coverage in U.S. markets and deepen our presence in the existing ones. Over the past 12 months, we have established encouraging talent presence within several new major metropolitan markets and anticipate these investments will drive meaningful impact in each region. More recently, we have continued to bolster these efforts with additional investments expected to contribute more substantially in 2027.
With the vast majority of roughly 1,800 high-volume shoulder specialists in the U.S. not yet using our platform, our expanded commercial leadership team has a long runway of greenfield opportunity ahead of it. Turning to innovation and our third strategic priority of developing and launching new technologies, most recently, we have moved our next-generation anatomic glenoid from the pipeline into the operating room, while during the third quarter, we expanded our N-22 line and continued to advance our development programs. I'll start with these two recent product introductions and then walk through updates on our enabling technology platform, our robotics program, and the pipeline projects we outlined last year. First, in early October, surgeons completed the first cases with InSet Go, our next-generation InSet anatomic glenoid, consistent with the timing we outlined on our last call.
InSet Go preserves the key design elements of our InSet glenoid, including our InSet Plus augmented options, while reducing the surgical steps involved. The surgeon response to InSet Go has been unanimously positive since launch. Second, we received FDA clearance for and launched our N-22 humeral head, extending our N-22 line for patients with metal hypersensitivity into anatomic procedures and building the uptake we've seen with the N-22's glenosphere on the reverse side. Combined with the other products we've launched over the past year, including our I-135RFX humeral stem and titanium plasma spray, or TPS, reverse base plate, the share of our procedures using at least one new product continued to tick up in the quarter. These launches also continue to support our average selling price.
Turning to enabling technology, during the quarter, we released a new version of ProVoyance, which we consider to be the main engagement center for our surgeons, that includes new features and security upgrades. These updates also build the planning foundation for our robotic technology known as InSet Neo. We connect to keeping the workflow simple and procedure times predictable for surgeons and enabling them to deliver the most accurate and effective surgery possible. As it relates to InSet Neo, development is progressing ahead of our initial internal timelines, and we remain on track for a planned FDA submission in the first half of 2027. Surgeon feedback on the portable case-by-case model continues to be very encouraging, and we look forward to sharing more on product features and our commercial approach as we near submission. Now for a few updates across the rest of our development pipeline.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
